Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 38Observational 2

Sponsor

Cancer Type

Endocrine 1Breast 1

Conditions

Breast Neoplasms 16Neoplasms 3Neoplasm Metastasis 2Multiple Endocrine Neoplasia Type 1 1Hormone Receptor Positive Advanced Breast Cancer 1HR+ Breast Cancer 1HER2-positive Metastatic Breast Cancer 1Breast Neoplasm Female 1Breast Diseases 1Breast Cancer Organoids 1

Interventions

Blood Specimen Collection 7Drug Therapy 6Surveys and Questionnaires 5Radiotherapy 5Radiosurgery 5Docetaxel 5Therapeutics 4Specimen Handling 4Immunotherapy 4Hepatectomy 4exemestane 3enzalutamide 3apalutamide 3Trastuzumab 3Hematologic Tests 3Data Collection 3Biopsy 3Biological Assay 3Anastrozole 3Abiraterone Acetate 3trastuzumab deruxtecan 2palbociclib 2darolutamide 2abiraterone 2abemaciclib 2Wearable Electronic Devices 2Triptorelin Pamoate 2Tamoxifen 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Neoplasm Metastasis × Fulvestrant × Clear all
NCT02753686 2023-02-15

Treat ER+ight

Novartis

Completed
440 enrolled
Endocrine

Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT01399086 2012-03-13

Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer

Hellenic Oncology Research Group

Completed
140 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡